By: Peter Lio, MD; Robert Sidbury, MD, MPH
This course has expired. You can still review the content but course credit is no longer available.
This certified CME activity is designed for dermatologists, dermatology nurse practitioners and dermatology physician assistants involved in the management of atopic dermatitis.
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals
Upon completion of this activity, the participant should be able to:
Accreditation Statement
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Evolve Medical Education LLC designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following faculty members have the following financial relationships with commercial interests:
Peter Lio, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Exeltis USA Dermatology, LLC; Galderma Laboratories L.P.; Johnson & Johnson; La Roche Posay; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; and Valeant Pharmaceuticals International, Inc. Grant/Research Support: AO Biome and La Fondation pour la Dermatite Atopique
Robert Sidbury, MD has had no financial agreements or affiliations during the past year.
Editorial Support Disclosure
Kristin Richardson, Writer and Cheryl Cavanaugh, MS, Evolve Medical Education LLC have no real or apparent conflicts of interest to report.
Rishi P. Singh, MD, Peer Reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan Inc.; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.